CN100531715C - 氨甲喋呤缓释注射剂 - Google Patents
氨甲喋呤缓释注射剂 Download PDFInfo
- Publication number
- CN100531715C CN100531715C CNB2006102000603A CN200610200060A CN100531715C CN 100531715 C CN100531715 C CN 100531715C CN B2006102000603 A CNB2006102000603 A CN B2006102000603A CN 200610200060 A CN200610200060 A CN 200610200060A CN 100531715 C CN100531715 C CN 100531715C
- Authority
- CN
- China
- Prior art keywords
- methotrexate
- release
- injection
- sustained
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940080182 methotrexate injection Drugs 0.000 title abstract 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims abstract description 147
- 229960000485 methotrexate Drugs 0.000 claims abstract description 147
- 239000002904 solvent Substances 0.000 claims abstract description 47
- 230000001093 anti-cancer Effects 0.000 claims abstract description 26
- 239000000375 suspending agent Substances 0.000 claims abstract description 22
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 10
- 239000000600 sorbitol Substances 0.000 claims abstract description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 9
- 229930195725 Mannitol Natural products 0.000 claims abstract description 9
- 239000000594 mannitol Substances 0.000 claims abstract description 9
- 235000010355 mannitol Nutrition 0.000 claims abstract description 9
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 4
- 239000007924 injection Substances 0.000 claims description 95
- 238000002347 injection Methods 0.000 claims description 95
- 238000013268 sustained release Methods 0.000 claims description 86
- 239000012730 sustained-release form Substances 0.000 claims description 86
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 57
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 40
- 239000004005 microsphere Substances 0.000 claims description 34
- 229960001338 colchicine Drugs 0.000 claims description 20
- 239000004480 active ingredient Substances 0.000 claims description 15
- 239000002504 physiological saline solution Substances 0.000 claims description 15
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 229940041181 antineoplastic drug Drugs 0.000 claims description 10
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 claims description 9
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 229950004403 polifeprosan Drugs 0.000 claims description 9
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 9
- ATZHGRNFEFVDDJ-UHFFFAOYSA-N 4-propylbenzoic acid Chemical compound CCCC1=CC=C(C(O)=O)C=C1 ATZHGRNFEFVDDJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000003080 antimitotic agent Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 abstract description 64
- 206010028980 Neoplasm Diseases 0.000 abstract description 63
- 239000000203 mixture Substances 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 22
- 229940100198 alkylating agent Drugs 0.000 abstract description 11
- 239000002168 alkylating agent Substances 0.000 abstract description 11
- 238000002360 preparation method Methods 0.000 abstract description 11
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract description 9
- 229920000053 polysorbate 80 Polymers 0.000 abstract description 9
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 abstract description 9
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 abstract description 9
- 235000010356 sorbitol Nutrition 0.000 abstract description 8
- 238000002513 implantation Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000009897 systematic effect Effects 0.000 abstract 1
- -1 mitopyrone Chemical compound 0.000 description 59
- 229940079593 drug Drugs 0.000 description 51
- 238000000034 method Methods 0.000 description 39
- 239000007943 implant Substances 0.000 description 32
- 229960004397 cyclophosphamide Drugs 0.000 description 29
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 28
- 229920001577 copolymer Polymers 0.000 description 28
- 238000012360 testing method Methods 0.000 description 24
- 239000004626 polylactic acid Substances 0.000 description 23
- 210000004881 tumor cell Anatomy 0.000 description 23
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 18
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 18
- JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 18
- ZMAODHOXRBLOQO-UHFFFAOYSA-N cytochalasin-A Natural products N1C(=O)C23OC(=O)C=CC(=O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 ZMAODHOXRBLOQO-UHFFFAOYSA-N 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 18
- 229920000747 poly(lactic acid) Polymers 0.000 description 17
- 229960001924 melphalan Drugs 0.000 description 16
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 14
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 description 14
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 description 14
- 229950006344 nocodazole Drugs 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 14
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- HRXVDDOKERXBEY-UHFFFAOYSA-N azatepa Chemical compound C1CN1P(=O)(N1CC1)N(CC)C1=NN=CS1 HRXVDDOKERXBEY-UHFFFAOYSA-N 0.000 description 12
- 229950002182 azatepa Drugs 0.000 description 12
- 229960001101 ifosfamide Drugs 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- JAABVEXCGCXWRR-FBXFSONDSA-N rel-norcantharidin Chemical compound C1C[C@H]2[C@@H]3C(=O)OC(=O)[C@@H]3[C@@H]1O2 JAABVEXCGCXWRR-FBXFSONDSA-N 0.000 description 12
- 229940095758 cantharidin Drugs 0.000 description 11
- 229930008397 cantharidin Natural products 0.000 description 11
- 239000002245 particle Substances 0.000 description 10
- 238000001694 spray drying Methods 0.000 description 10
- GDFUWFOCYZZGQU-UHFFFAOYSA-N 4-propoxybenzoic acid Chemical compound CCCOC1=CC=C(C(O)=O)C=C1 GDFUWFOCYZZGQU-UHFFFAOYSA-N 0.000 description 9
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 9
- 229920000954 Polyglycolide Polymers 0.000 description 9
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 9
- 229950011260 betanaphthol Drugs 0.000 description 9
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 9
- 229950008097 improsulfan Drugs 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 229960000350 mitotane Drugs 0.000 description 9
- QXYYYPFGTSJXNS-UHFFFAOYSA-N mitozolomide Chemical compound N1=NN(CCCl)C(=O)N2C1=C(C(=O)N)N=C2 QXYYYPFGTSJXNS-UHFFFAOYSA-N 0.000 description 9
- 229950005967 mitozolomide Drugs 0.000 description 9
- 229960000952 pipobroman Drugs 0.000 description 9
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 9
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 9
- 229950001100 piposulfan Drugs 0.000 description 9
- 239000004633 polyglycolic acid Substances 0.000 description 9
- YNXICDMQCQPQEW-UHFFFAOYSA-N 1-naphthyl dihydrogen phosphate Chemical compound C1=CC=C2C(OP(O)(=O)O)=CC=CC2=C1 YNXICDMQCQPQEW-UHFFFAOYSA-N 0.000 description 8
- FJDBYGKCGURUGE-NTISSMGPSA-N 2-hydroxybenzoic acid;n-[(7s)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide Chemical compound OC(=O)C1=CC=CC=C1O.C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC FJDBYGKCGURUGE-NTISSMGPSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 6
- 230000002601 intratumoral effect Effects 0.000 description 6
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 6
- 239000000693 micelle Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- XNWUTCRFGMBUOP-UHFFFAOYSA-N 1,4-bis(oxiran-2-ylmethyl)piperazine Chemical compound C1CN(CC2OC2)CCN1CC1CO1 XNWUTCRFGMBUOP-UHFFFAOYSA-N 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 239000005822 Propiconazole Substances 0.000 description 4
- 229920005578 aromatic polyanhydride Polymers 0.000 description 4
- 229920001400 block copolymer Polymers 0.000 description 4
- 239000003405 delayed action preparation Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229960003539 mitoguazone Drugs 0.000 description 4
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 4
- STJLVHWMYQXCPB-UHFFFAOYSA-N propiconazole Chemical compound O1C(CCC)COC1(C=1C(=CC(Cl)=CC=1)Cl)CN1N=CN=C1 STJLVHWMYQXCPB-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 3
- UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000002927 anti-mitotic effect Effects 0.000 description 3
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 238000007334 copolymerization reaction Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- CMEGANPVAXDBPL-INIZCTEOSA-N n-[(7s)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(SC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC CMEGANPVAXDBPL-INIZCTEOSA-N 0.000 description 3
- BRZOTEHEMOQUOY-UHFFFAOYSA-N n-[bis(aziridin-1-yl)phosphoryl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NP(=O)(N1CC1)N1CC1 BRZOTEHEMOQUOY-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 229920002567 Chondroitin Polymers 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- YADZBEISHVCBSJ-UHFFFAOYSA-N [I].OCC(O)CO Chemical compound [I].OCC(O)CO YADZBEISHVCBSJ-UHFFFAOYSA-N 0.000 description 2
- 229940022663 acetate Drugs 0.000 description 2
- 229950003478 acodazole Drugs 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229920005576 aliphatic polyanhydride Polymers 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 229950005994 giracodazole Drugs 0.000 description 2
- YILCGOCHVFQMTC-WVZVXSGGSA-N girolline Chemical compound NC[C@H](Cl)[C@@H](O)C1=CNC(N)=N1 YILCGOCHVFQMTC-WVZVXSGGSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940099584 lactobionate Drugs 0.000 description 2
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960001474 meclozine Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229960001252 methamphetamine Drugs 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- QTFKTBRIGWJQQL-UHFFFAOYSA-N meturedepa Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 2
- 229950009847 meturedepa Drugs 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 229960001082 trimethoprim Drugs 0.000 description 2
- SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 2
- 229950006929 uredepa Drugs 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- MJRDZKSKNYIAHZ-WLHGVMLRSA-N (e)-but-2-enedioic acid;decanedioic acid Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)CCCCCCCCC(O)=O MJRDZKSKNYIAHZ-WLHGVMLRSA-N 0.000 description 1
- RWLDMKWISBAJSN-UHFFFAOYSA-N 1,2,2,3,4,4-hexamethylpyrimidine Chemical compound CC1(N(C(N(C=C1)C)(C)C)C)C RWLDMKWISBAJSN-UHFFFAOYSA-N 0.000 description 1
- WFJFGMLKAISFOZ-UHFFFAOYSA-N 1-amino-3-iminourea Chemical compound NN=C(O)N=N WFJFGMLKAISFOZ-UHFFFAOYSA-N 0.000 description 1
- XXVLKDRPHSFIIB-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 XXVLKDRPHSFIIB-UHFFFAOYSA-N 0.000 description 1
- PBUUPFTVAPUWDE-UGZDLDLSSA-N 2-[[(2S,4S)-2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda5-oxazaphosphinan-4-yl]sulfanyl]ethanesulfonic acid Chemical compound OS(=O)(=O)CCS[C@H]1CCO[P@](=O)(N(CCCl)CCCl)N1 PBUUPFTVAPUWDE-UGZDLDLSSA-N 0.000 description 1
- 150000004786 2-naphthols Chemical class 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241001289435 Astragalus brachycalyx Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Guatambuinine Natural products N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000234479 Narcissus Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229920001273 Polyhydroxy acid Polymers 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000005828 Pyrimethanil Substances 0.000 description 1
- SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000907663 Siproeta stelenes Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102400000160 Thymopentin Human genes 0.000 description 1
- 101800001703 Thymopentin Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- DAKNGOHARFHXAC-UHFFFAOYSA-N [4,6-bis(hydroxymethyl)triazin-5-yl]methanol Chemical compound OCC1=NN=NC(CO)=C1CO DAKNGOHARFHXAC-UHFFFAOYSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RIOXQFHNBCKOKP-UHFFFAOYSA-N benomyl Chemical compound C1=CC=C2N(C(=O)NCCCC)C(NC(=O)OC)=NC2=C1 RIOXQFHNBCKOKP-UHFFFAOYSA-N 0.000 description 1
- 229950005567 benzodepa Drugs 0.000 description 1
- MITFXPHMIHQXPI-UHFFFAOYSA-N benzoxaprofen Natural products N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- LPRCVLBATUMNBP-UHFFFAOYSA-N decanedioic acid;propane Chemical compound CCC.OC(=O)CCCCCCCCC(O)=O LPRCVLBATUMNBP-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical class CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- VPVSTMAPERLKKM-UHFFFAOYSA-N glycoluril Chemical compound N1C(=O)NC2NC(=O)NC21 VPVSTMAPERLKKM-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000012155 injection solvent Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229950000547 mafosfamide Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- UUVIQYKKKBJYJT-ZYUZMQFOSA-N mannosulfan Chemical compound CS(=O)(=O)OC[C@@H](OS(C)(=O)=O)[C@@H](O)[C@H](O)[C@H](OS(C)(=O)=O)COS(C)(=O)=O UUVIQYKKKBJYJT-ZYUZMQFOSA-N 0.000 description 1
- 229960000733 mannosulfan Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229950008144 mitoclomine Drugs 0.000 description 1
- 229950001745 mitonafide Drugs 0.000 description 1
- 229950005715 mitosper Drugs 0.000 description 1
- 229950000163 mitotenamine Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- CLZXREZAEIUCGG-UHFFFAOYSA-N n,n-bis(2-chloroethyl)-4-methoxy-3-methylnaphthalen-1-amine Chemical compound C1=CC=C2C(OC)=C(C)C=C(N(CCCl)CCCl)C2=C1 CLZXREZAEIUCGG-UHFFFAOYSA-N 0.000 description 1
- SZLHBBCRNVPTRZ-UHFFFAOYSA-N n-[(5-bromo-1-benzothiophen-3-yl)methyl]-2-chloro-n-ethylethanamine Chemical compound C1=C(Br)C=C2C(CN(CCCl)CC)=CSC2=C1 SZLHBBCRNVPTRZ-UHFFFAOYSA-N 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- YNXICDMQCQPQEW-UHFFFAOYSA-L naphthalen-1-yl phosphate Chemical compound C1=CC=C2C(OP([O-])(=O)[O-])=CC=CC2=C1 YNXICDMQCQPQEW-UHFFFAOYSA-L 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 206010061311 nervous system neoplasm Diseases 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- VPAWVRUHMJVRHU-VGDKGRGNSA-N perfosfamide Chemical compound OO[C@@H]1CCO[P@@](=O)(N(CCCl)CCCl)N1 VPAWVRUHMJVRHU-VGDKGRGNSA-N 0.000 description 1
- 229950009351 perfosfamide Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- XYWJNTOURDMTPI-UHFFFAOYSA-N procodazole Chemical compound C1=CC=C2NC(CCC(=O)O)=NC2=C1 XYWJNTOURDMTPI-UHFFFAOYSA-N 0.000 description 1
- 229950000989 procodazole Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
- 229960004517 thymopentin Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030829 thyroid gland adenocarcinoma Diseases 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
试验组(n) | 给药方式 | 肿瘤体积(cm<sup>3</sup>) | P值 |
1(6) | - | 70 | |
2(6) | 尾静脉注射普通注射剂 | 68 | 0.05 |
3(6) | 腹腔注射普通注射剂 | 64 | 0.05 |
4(6) | 瘤周注射普通注射剂 | 56 | 0.04 |
5(6) | 瘤周注射缓释注射剂 | 34 | <0.01 |
6(6) | 瘤周放置缓释植入剂 | 22 | <0.01 |
7(6) | 瘤内注射普通注射剂 | 52 | 0.03 |
8(6) | 瘤内注射缓释注射剂 | 20 | <0.001 |
9(6) | 瘤内放置缓释植入剂 | 18 | <0.001 |
试验组(n) | 所受治疗 | 肿瘤体积(cm<sup>3</sup>) | P值 |
1(6) | 对照 | 60±10 | |
2(6) | 氨甲喋呤 | 42±5.4 | <0.05 |
3(6) | 秋水仙碱 | 46±2.0 | <0.01 |
4(6) | β-萘酚 | 40±2.2 | <0.01 |
5(6) | 阿考达唑 | 44±3.2 | <0.01 |
6(6) | 细胞松驰素 | 40±3.0 | <0.01 |
7(6) | 氨甲喋呤+秋水仙碱 | 32±2.0 | <0.001 |
8(6) | 氨甲喋呤+β-萘酚 | 30±1.8 | <0.001 |
9(6) | 氨甲喋呤+阿考达唑 | 34±3.0 | <0.001 |
10(6) | 氨甲喋呤+细胞松驰素 | 18±2.2 | <0.001 |
瘤细胞 | 氨甲喋呤 | 丙考达唑 | 砒霜 | 诺考达唑 | 氨甲喋呤+丙考达唑 | 氨甲喋呤+砒霜 | 氨甲喋呤+诺考达唑 |
CNS | 46% | 46% | 60% | 56% | 92% | 88% | 94% |
C6 | 44% | 54% | 60% | 60% | 94% | 89% | 90% |
SA | 38% | 52% | 52% | 62% | 86% | 90% | 92% |
BC | 34% | 54% | 50% | 60% | 92% | 84% | 88% |
BA | 38% | 50% | 58% | 62% | 92% | 90% | 90% |
LH | 40% | 48% | 58% | 56% | 90% | 84% | 88% |
PAT | 50% | 48% | 54% | 50% | 92% | 88% | 90% |
试验组(n) | 所受治疗 | 肿瘤体积(cm<sup>3</sup>) | P值 |
1(6) | 对照 | 60±10 | |
2(6) | 环磷酰胺 | 42±5.0 | <0.05 |
3(6) | 氨甲喋呤 | 36±2.0 | <0.01 |
4(6) | 环磷酰胺+氨甲喋呤 | 24±1.4 | <0.001 |
5(6) | 美法仑 | 38±2.0 | <0.01 |
6(6) | 美法仑+氨甲喋呤 | 24±2.0 | <0.001 |
7(6) | 瘤可宁 | 36±3.0 | <0.01 |
8(6) | 瘤可宁+氨甲喋呤 | 18±2.0 | <0.001 |
9(6) | 异环磷酰胺 | 40±4.6 | <0.01 |
10(6) | 异环磷酰胺+氨甲喋呤 | 18±1.8 | <0.001 |
试验组(n) | 所受治疗 | 肿瘤抑制率(%) | P值 |
1(6) | 对照 | - | |
2(6) | 氨甲喋呤 | 48 | <0.05 |
3(6) | 4H-过氧环磷酰胺 | 46 | <0.01 |
4(6) | 地磷酰胺 | 36 | <0.01 |
5(6) | 马磷酰胺 | 42 | <0.01 |
6(6) | 培磷酰胺 | 46 | <0.01 |
7(6) | 氨甲喋呤+4H-过氧环磷酰胺 | 92 | <0.001 |
8(6) | 氨甲喋呤+地磷酰胺 | 80 | <0.001 |
9(6) | 氨甲喋呤+马磷酰胺 | 86 | <0.001 |
10(6) | 氨甲喋呤+培磷酰胺 | 90 | <0.001 |
试验组(n) | 所受治疗 | 肿瘤抑制率(%) | P值 |
1(6) | 对照 | - | |
2(6) | 氨甲喋呤 | 56 | <0.05 |
3(6) | 六甲嘧胺 | 52 | <0.01 |
4(6) | 斑蝥素 | 46 | <0.01 |
5(6) | 去甲斑蝥素 | 42 | <0.01 |
6(6) | 甘露舒凡 | 46 | <0.01 |
7(6) | 氨甲喋呤+六甲嘧胺 | 86 | <0.001 |
8(6) | 氨甲喋呤+斑蝥素 | 80 | <0.001 |
9(6) | 氨甲喋呤+去甲斑蝥素 | 92 | <0.001 |
10(6) | 氨甲喋呤+甘露舒凡 | 82 | <0.001 |
试验组(n) | 所受治疗 | 肿瘤抑制率(%) | P值 |
1(6) | 对照 | - | |
2(6) | 氨甲喋呤 | 52 | <0.05 |
3(6) | 曲奥舒凡 | 40 | <0.05 |
4(6) | 利曲舒凡 | 42 | <0.05 |
5(6) | 英丙舒凡 | 52 | <0.05 |
6(6) | 依托格鲁 | 60 | <0.01 |
7(6) | 氨甲喋呤+曲奥舒凡 | 78 | <0.01 |
8(6) | 氨甲喋呤+利曲舒凡 | 82 | <0.01 |
9(6) | 氨甲喋呤+英丙舒凡 | 88 | <0.01 |
10(6) | 氨甲喋呤+依托格鲁 | 82 | <0.001 |
试验组(n) | 所受治疗 | 肿瘤抑制率(%) | P值 |
1(6) | 对照 | - | |
2(6) | 氨甲喋呤 | 58 | <0.05 |
3(6) | 癌宁 | 42 | <0.01 |
4(6) | 环氧哌嗪 | 32 | <0.01 |
5(6) | 乌瑞替哌 | 32 | <0.01 |
6(6) | 阿扎替哌 | 44 | <0.01 |
7(6) | 氨甲喋呤+癌宁 | 80 | <0.001 |
8(6) | 氨甲喋呤+环氧哌嗪 | 70 | <0.001 |
9(6) | 氨甲喋呤+乌瑞替哌 | 92 | <0.001 |
10(6) | 氨甲喋呤+阿扎替哌 | 90 | <0.001 |
溶媒黏度(cp) | 注射成功次数 | 注射成功率(%) |
10 | 1 | 5 |
50 | 2 | 10 |
100 | 4 | 20 |
200 | 7 | 35 |
300 | 9 | 45 |
400 | 12 | 60 |
500 | 14 | 70 |
550 | 14 | 70 |
600 | 16 | 80 |
650 | 18 | 90 |
Claims (1)
- 【权利要求1】一种含氨甲喋呤的抗癌药物缓释注射剂,由以下成分组成:(A)缓释微球,包括:抗癌有效成分缓释辅料和(B)溶媒;其中,抗癌有效成分为氨甲喋呤与选自抗有丝分裂药物的氨甲喋呤增效剂的组合;溶媒中的助悬剂为甘露醇或山梨醇;所述的抗癌药物缓释注射剂的组分为下列组合之一:(1)抗癌有效成分为10%氨甲喋呤和10%秋水仙碱,缓释辅料为对羧苯基丙烷:癸二酸为20:80的聚苯丙生,溶媒为含15%甘露醇的生理盐水;(2)抗癌有效成分为20%氨甲喋呤和10%阿考达唑,缓释辅料为乙烯乙酸乙烯酯共聚物,溶媒为含5-15%山梨醇的注射液;抗癌有效成分的重量百分比基于微球,助悬剂为体积重量比基于溶媒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006102000603A CN100531715C (zh) | 2006-01-23 | 2006-01-23 | 氨甲喋呤缓释注射剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006102000603A CN100531715C (zh) | 2006-01-23 | 2006-01-23 | 氨甲喋呤缓释注射剂 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA200810302967XA Division CN101380298A (zh) | 2006-01-23 | 2006-01-23 | 氨甲喋呤缓释注射剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1846680A CN1846680A (zh) | 2006-10-18 |
CN100531715C true CN100531715C (zh) | 2009-08-26 |
Family
ID=37076564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006102000603A Expired - Fee Related CN100531715C (zh) | 2006-01-23 | 2006-01-23 | 氨甲喋呤缓释注射剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100531715C (zh) |
-
2006
- 2006-01-23 CN CNB2006102000603A patent/CN100531715C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1846680A (zh) | 2006-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101433520A (zh) | 含埃坡霉素的抗癌缓释剂 | |
CN1969818A (zh) | 一种含埃坡霉素衍生物的抗癌缓释注射剂 | |
CN1969816A (zh) | 一种含埃坡霉素的抗癌缓释剂 | |
CN101396340A (zh) | 一种含埃坡霉素衍生物的抗癌缓释注射剂 | |
CN101396342A (zh) | 含埃坡霉素衍生物的抗癌缓释注射剂 | |
CN101380303A (zh) | 一种同载铂类化合物及其增效剂的抗癌药物缓释注射剂 | |
CN1969825A (zh) | 一种氟尿嘧啶及其增效剂的缓释剂 | |
CN100500215C (zh) | 含氨甲喋呤及其增效剂的缓释注射剂 | |
CN100531715C (zh) | 氨甲喋呤缓释注射剂 | |
CN1969823A (zh) | 一种含氟尿嘧啶及其增效剂的缓释剂 | |
CN1969824A (zh) | 一种含氟尿嘧啶及其增效剂的抗癌缓释剂 | |
CN100531718C (zh) | 含氨甲喋呤增效剂的缓释注射剂 | |
CN101380298A (zh) | 氨甲喋呤缓释注射剂 | |
CN1969828A (zh) | 一种含间质水解剂的抗癌缓释注射剂 | |
CN1969826A (zh) | 一种载氟尿嘧啶及其增效剂的缓释剂 | |
CN1839843A (zh) | 氟尿嘧啶缓释注射剂 | |
CN100531719C (zh) | 含氨甲喋呤增效剂的缓释注射剂 | |
CN101254166A (zh) | 同载克罗拉滨及其增效剂的抗癌药物缓释注射剂 | |
CN1969821A (zh) | 一种同载抗癌药物和增效剂的抗癌缓释剂 | |
CN101380307A (zh) | 同载抗癌药物和增效剂的抗癌缓释剂 | |
CN101837002A (zh) | 一种抗癌缓释注射剂 | |
CN101011343A (zh) | 一种含抗代谢类药物及烷化剂的缓释注射剂 | |
CN101427996A (zh) | 一种新的抗癌缓释注射剂 | |
CN101390827A (zh) | 含氨甲喋呤增效剂的缓释注射剂 | |
CN1961863A (zh) | 一种含间质水解剂和细胞毒药物的抗癌缓释剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Patentee after: Jinan Shuaihua Pharmaceutical Technology Co., Ltd. Address before: 202, room 2, building 19, Pioneer Park, No. 250100 Huaneng Road, Shandong, Ji'nan Patentee before: Jinan Shuaihua Pharmaceutical Technology Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SHANDONG ENDUO BIO-PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: JINAN SHUAIHUA MEDICINE TECHNOLOGY CO., LTD. Effective date: 20110525 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 NO. 1750, TIANCHEN ROAD, HIGH-TECH. ZONE, JI NAN CITY, SHANDONG PROVINCE TO: 250101 201, NO. 1750, TIANCHEN ROAD, HIGH-TECH. ZONE, JI NAN CITY, SHANDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110525 Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 201 Patentee after: Shandong many biological pharmaceutical Co., Ltd. Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Patentee before: Jinan Shuaihua Pharmaceutical Technology Co., Ltd. |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090826 Termination date: 20120123 |